scg101
Cell therapyexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
3
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 14, 2021 (NCT05339321)
Timeline
2020s
- Jan 1, 2021
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Hepatitis B virusImmunity, passive
Hepatitis B virus immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT05417932 | Phase 1/Phase 2 (Phase 2) | Oct 26, 2022 | SCG Cell Therapy Pte. Ltd. |
| NCT06617000 | Phase 1 | Oct 25, 2022 | SCG Cell Therapy Pte. Ltd. |
| NCT05339321 | Phase 1 | Apr 14, 2021 | Chinese Academy of Medical Sciences |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| SCG Cell Therapy Pte. Ltd. | For profit | 2 | 2 | 2 | 2022 |
| Chinese Academy of Medical Sciences | Academic/Hospital | 1 | 1 | 1 | 2021 |
2 organizations
Page 1 / 1